Abstract

Overall response to consent (Yes%/No%/Unknown %): 99% Yes Total individual cases held: 1,000 % cases associated with fresh-frozen tumor biospecimens: 65% % cases with paraffin embedded biospecimens: 80% % cases with blood and blood derivatives: 93%
The most valuable cases are those that have more than 5 years follow-up data associated with them. This should include what treatment these patients have had so that appropriate outcome data can be incorporated in to any molecular analysis.
The major challenges we face are accurate patient information that includes a range of indicators that are followed-up on a regular basis.
The most important thing would be to implement data linkage programs to other data repositories such as the NSW Centre for Health Record Linkage program.
